Go Back This article was viewed 109 times

Brief Commentary


Molecular triage of lung cancer for targeted therapy

Tanushree Mukherjee
Department of Pathology, Command Hospital, Chandimandir, Kolkata, West Bengal, India
Corresponding Author:

Tanushree Mukherjee

Department of Pathology, Command Hospital, Chandimandir, Kolkata, West Bengal, India
E-mail: Tanujamukherjee@yahoo.com

Corresponding Author:

Tanushree Mukherjee

Department of Pathology, Command Hospital, Chandimandir, Kolkata, West Bengal, India
E-mail: Tanujamukherjee@yahoo.com

DOI:10.18203/issn.2456-3994.IntJMolImmunoOncol20184344

ABSTRACT


The type of lung cancer as per histology is small cell and non-small cell carcinoma which includes adenocarcinoma with variants, squamous carcinoma. Biomolecular testing[1-3] includes tests of genes or proteins required to analyze which can be targeted with therapy to treat the patients. Molecular diagnostics-guided targeted therapies have become a standard treatment for patients with lung cancer. Driver genetic alterations such as epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) rearrangements are currently used as predictive biomarkers for EGFR tyrosine kinase inhibitors and ALK inhibitors, respectively.
Keywords: Molecular triage, Lung cancer, NSCLC

This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-Share Alike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.